Preclinical evaluation of the reliability of a 50 MeV racetrack microtron.

PURPOSE: A 50 MeV racetrack microtron has been installed and tested at Memorial Sloan-Kettering Cancer Center. It is designed to execute multi-segment conformal therapy automatically under computer control using scanned X ray and electron beams from 10 to 50 MeV. Prior to acceptance of the machine from the manufacturer, formal reliability testing was carried out. Only in this way could confidence be gained in its usefulness for routine 3D computer-controlled conformal therapy. MATERIALS AND METHODS: To assess reliability, a set of 25 multi-segment test cases, each consisting of 10 to 17 fixed segments, was developed. The field arrangements and modalities for some of the test cases were identical to 3D conformal treatments that were being delivered with multiple static fields on conventional linear accelerators at our institution. Other cases were designed to explore reliability under more complex sets of conditions. These cases were "treated" repeatedly during a total period of 45 hours, over 5 days. During the treatments, ion chambers attached to the head of the machine provided dosimetric data for each field. Data from sensors connected to every set-up parameter (for example, couch positions, gantry angle, collimator leaf positions, etc.) were recorded and verified by an external computer. RESULTS: While preliminary tests indicated an interlock rate of 5%, final reliability test results demonstrated an interlock fault rate of approximately 0.5%. The reproducibility of dosimetric data and geometric setup parameters was within specifications. As an example, leaf position reproducibility in the patient plane was within 0.5 mm for 97% of the setups. The times required to carry out treatments were recorded and compared with the times to carry out identical treatments on a conventional linear accelerator with cerrobend blocks. Areas where additional time savings can be achieved were identified. CONCLUSIONS: As an integral part of acceptance testing, the Scanditronix MM50 was rigorously tested for reliability. The machine successfully passed these tests, providing increased confidence in its usefulness for routine 3D conformal therapy.

Pretransfusion blood irradiation: clinical rationale and dosimetric considerations.

The irradiation of blood before transfusion into immunosuppressed patients is an increasingly common technique used to prevent graft-versus-host disease. A technical procedure is described for the calibration of blood irradiators, including the determination of absolute dose rate and relative dose distribution over the blood volume. Results of dose rate measurements on commercially available irradiators indicate differences of +5% to -13% with manufacturer-supplied calibrations and variations in the relative dose rate over the irradiation volume from 70% to 180%. The clinical implications of these findings and the need for accurate dosimetry are discussed.

Beam characteristics of a new generation 50 MeV racetrack microtron.

The first of a new generation of microtron accelerators has been installed and tested. It is currently in use for multisegment conformal radiotherapy at our institution. The unit produces x rays and electrons from 10 to 50 MeV in 5 MeV increments. It incorporates a 64 leaf, doubly focused multileaf collimator (MLC), which can be used to shape x-ray and electron beams. Both x-ray and electron beams are produced by magnetically scanning the electron beams from the accelerator. The new generation unit incorporates a purging magnet to sweep away any primary or secondary electrons that pass through the target(s). In this paper, the beam characteristics of the accelerator that were studied during acceptance testing are described. Representative examples of depth doses, beam profiles, output factors, and elementary beam distributions are presented and discussed, in comparison with the earlier generation of microtron accelerators and with other radiotherapy machines.

Calculated and TLD-based absorbed dose estimates for I-131-labeled 3F8 monoclonal antibody in a human neuroblastoma xenograft nude mouse model.

Preclinical evaluation of the therapeutic potential of radiolabeled antibodies is commonly performed in a xenografted nude mouse model. To assess therapeutic efficacy it is important to estimate the absorbed dose to the tumor and normal tissues of the nude mouse. The current study was designed to accurately measure radiation does to human neuroblastoma xenografts and normal organs in nude mice treated with I-131-labeled 3F8 monoclonal antibody (MoAb) against disialoganglioside GD2 antigen. Absorbed dose estimates were obtained using two different approaches: (1) measurement with teflon-imbedded CaSO4:Dy mini-thermoluminescent dosimeters (TLDs) and (2) calculations using mouse S-factors. The calculated total dose to tumor one week after i.v. injection of the 50 microCi I-131-3F8 MoAb was 604 cGy. The corresponding decay corrected and not corrected TLD measurements were 109 +/- 9 and 48.7 +/- 3.4 cGy respectively. The calculated to TLD-derived dose ratios for tumor ranged from 6.1 at 24 h to 5.5 at 1 week. The light output fading rate was found to depend upon the tissue type within which the TLDs were implanted. The decay rate in tumor, muscle, subcutaneous tissue and in vitro, were 9.5, 5.0, 3.7 and 0.67% per day, respectively. We have demonstrated that the type of tissue in which the TLD was implanted strongly influenced the in vivo decay of light output. Even with decay correction, a significant discrepancy was observed between MIRD-based calculated and CaSO4:Dy mini-TLD measured absorbed doses. Batch dependence, pH of the tumor or other variables associated with TLDs which are not as yet well known may account for this discrepancy.